Effects of hypokalaemia on arrhythmogenic risk of quinidine in rats

Michiko Hirota, Hisakazu Ohtani, Erika Hanada, Hajime Kotaki, Yasufumi Sawada, Tatsuji Iga

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Plasma potassium concentration plays an important role in the induction of arrhythmia and is closely related to the arrhythmogenicity of various drugs. We quantitatively analyzed the influence of plasma potassium concentration on QT intervals before drug administration and on drug-induced QT prolongation, to estimate the risk of drug-induced arrhythmia under hypokalaemic conditions. The hypokalaemic models were produced by intraperitoneal administration of furosemide and hydrochlorothiazide in male Sprague-Dawley rats. The relationship between the changes in QT intervals and time profiles of plasma quinidine (QND) concentration were analyzed during constant intravenous infusion of QND (10 or 30 mg/kg/h) and post infusion in normal and hypokalaemic rats. The plasma QND concentration reached the therapeutic range (3-7 μg/ml) at the high infusion rate (30 mg/kg/h). No pharmacokinetic differences between normal and hypokalaemic rats were observed. QND induced QT prolongation in parallel with the plasma concentration without hysteresis. Although the potency of QND for QT prolongation was not affected by hypokalaemia, the QT intervals before drug administration were significantly prolonged in hypokalaemic rats (65.90 ± 1.40 vs 56.60 ± 0.748 msec, mean ± SEM, p < 0.0001). Thus, the prolongation of QT intervals before drug administration may act as a risk factor of arrhythmia under hypokalaemic conditions.

Original languageEnglish
Pages (from-to)2159-2169
Number of pages11
JournalLife Sciences
Volume62
Issue number24
DOIs
Publication statusPublished - 1998 May 8
Externally publishedYes

Fingerprint

Quinidine
Hypokalemia
Rats
Plasmas
Pharmaceutical Preparations
Cardiac Arrhythmias
Potassium
Hydrochlorothiazide
Pharmacokinetics
Furosemide
Intravenous Infusions
Sprague Dawley Rats
Hysteresis
Scanning electron microscopy

Keywords

  • Arrhythmia
  • Electrocadiography
  • Hypokalaemia
  • Potassium
  • QT interval
  • Quinidine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effects of hypokalaemia on arrhythmogenic risk of quinidine in rats. / Hirota, Michiko; Ohtani, Hisakazu; Hanada, Erika; Kotaki, Hajime; Sawada, Yasufumi; Iga, Tatsuji.

In: Life Sciences, Vol. 62, No. 24, 08.05.1998, p. 2159-2169.

Research output: Contribution to journalArticle

Hirota, M, Ohtani, H, Hanada, E, Kotaki, H, Sawada, Y & Iga, T 1998, 'Effects of hypokalaemia on arrhythmogenic risk of quinidine in rats', Life Sciences, vol. 62, no. 24, pp. 2159-2169. https://doi.org/10.1016/S0024-3205(98)00193-3
Hirota, Michiko ; Ohtani, Hisakazu ; Hanada, Erika ; Kotaki, Hajime ; Sawada, Yasufumi ; Iga, Tatsuji. / Effects of hypokalaemia on arrhythmogenic risk of quinidine in rats. In: Life Sciences. 1998 ; Vol. 62, No. 24. pp. 2159-2169.
@article{81784e1074c3486b9258b661adf84408,
title = "Effects of hypokalaemia on arrhythmogenic risk of quinidine in rats",
abstract = "Plasma potassium concentration plays an important role in the induction of arrhythmia and is closely related to the arrhythmogenicity of various drugs. We quantitatively analyzed the influence of plasma potassium concentration on QT intervals before drug administration and on drug-induced QT prolongation, to estimate the risk of drug-induced arrhythmia under hypokalaemic conditions. The hypokalaemic models were produced by intraperitoneal administration of furosemide and hydrochlorothiazide in male Sprague-Dawley rats. The relationship between the changes in QT intervals and time profiles of plasma quinidine (QND) concentration were analyzed during constant intravenous infusion of QND (10 or 30 mg/kg/h) and post infusion in normal and hypokalaemic rats. The plasma QND concentration reached the therapeutic range (3-7 μg/ml) at the high infusion rate (30 mg/kg/h). No pharmacokinetic differences between normal and hypokalaemic rats were observed. QND induced QT prolongation in parallel with the plasma concentration without hysteresis. Although the potency of QND for QT prolongation was not affected by hypokalaemia, the QT intervals before drug administration were significantly prolonged in hypokalaemic rats (65.90 ± 1.40 vs 56.60 ± 0.748 msec, mean ± SEM, p < 0.0001). Thus, the prolongation of QT intervals before drug administration may act as a risk factor of arrhythmia under hypokalaemic conditions.",
keywords = "Arrhythmia, Electrocadiography, Hypokalaemia, Potassium, QT interval, Quinidine",
author = "Michiko Hirota and Hisakazu Ohtani and Erika Hanada and Hajime Kotaki and Yasufumi Sawada and Tatsuji Iga",
year = "1998",
month = "5",
day = "8",
doi = "10.1016/S0024-3205(98)00193-3",
language = "English",
volume = "62",
pages = "2159--2169",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "24",

}

TY - JOUR

T1 - Effects of hypokalaemia on arrhythmogenic risk of quinidine in rats

AU - Hirota, Michiko

AU - Ohtani, Hisakazu

AU - Hanada, Erika

AU - Kotaki, Hajime

AU - Sawada, Yasufumi

AU - Iga, Tatsuji

PY - 1998/5/8

Y1 - 1998/5/8

N2 - Plasma potassium concentration plays an important role in the induction of arrhythmia and is closely related to the arrhythmogenicity of various drugs. We quantitatively analyzed the influence of plasma potassium concentration on QT intervals before drug administration and on drug-induced QT prolongation, to estimate the risk of drug-induced arrhythmia under hypokalaemic conditions. The hypokalaemic models were produced by intraperitoneal administration of furosemide and hydrochlorothiazide in male Sprague-Dawley rats. The relationship between the changes in QT intervals and time profiles of plasma quinidine (QND) concentration were analyzed during constant intravenous infusion of QND (10 or 30 mg/kg/h) and post infusion in normal and hypokalaemic rats. The plasma QND concentration reached the therapeutic range (3-7 μg/ml) at the high infusion rate (30 mg/kg/h). No pharmacokinetic differences between normal and hypokalaemic rats were observed. QND induced QT prolongation in parallel with the plasma concentration without hysteresis. Although the potency of QND for QT prolongation was not affected by hypokalaemia, the QT intervals before drug administration were significantly prolonged in hypokalaemic rats (65.90 ± 1.40 vs 56.60 ± 0.748 msec, mean ± SEM, p < 0.0001). Thus, the prolongation of QT intervals before drug administration may act as a risk factor of arrhythmia under hypokalaemic conditions.

AB - Plasma potassium concentration plays an important role in the induction of arrhythmia and is closely related to the arrhythmogenicity of various drugs. We quantitatively analyzed the influence of plasma potassium concentration on QT intervals before drug administration and on drug-induced QT prolongation, to estimate the risk of drug-induced arrhythmia under hypokalaemic conditions. The hypokalaemic models were produced by intraperitoneal administration of furosemide and hydrochlorothiazide in male Sprague-Dawley rats. The relationship between the changes in QT intervals and time profiles of plasma quinidine (QND) concentration were analyzed during constant intravenous infusion of QND (10 or 30 mg/kg/h) and post infusion in normal and hypokalaemic rats. The plasma QND concentration reached the therapeutic range (3-7 μg/ml) at the high infusion rate (30 mg/kg/h). No pharmacokinetic differences between normal and hypokalaemic rats were observed. QND induced QT prolongation in parallel with the plasma concentration without hysteresis. Although the potency of QND for QT prolongation was not affected by hypokalaemia, the QT intervals before drug administration were significantly prolonged in hypokalaemic rats (65.90 ± 1.40 vs 56.60 ± 0.748 msec, mean ± SEM, p < 0.0001). Thus, the prolongation of QT intervals before drug administration may act as a risk factor of arrhythmia under hypokalaemic conditions.

KW - Arrhythmia

KW - Electrocadiography

KW - Hypokalaemia

KW - Potassium

KW - QT interval

KW - Quinidine

UR - http://www.scopus.com/inward/record.url?scp=0032496118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032496118&partnerID=8YFLogxK

U2 - 10.1016/S0024-3205(98)00193-3

DO - 10.1016/S0024-3205(98)00193-3

M3 - Article

C2 - 9627074

AN - SCOPUS:0032496118

VL - 62

SP - 2159

EP - 2169

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 24

ER -